MARKET

HROW

HROW

Harrow Health Inc
NASDAQ
42.07
+0.57
+1.37%
After Hours: 41.51 -0.56 -1.33% 16:39 06/26 EDT
OPEN
41.30
PREV CLOSE
41.50
HIGH
42.28
LOW
40.50
VOLUME
1.52M
TURNOVER
--
52 WEEK HIGH
54.85
52 WEEK LOW
28.54
MARKET CAP
1.57B
P/E (TTM)
-102.8858
1D
5D
1M
3M
1Y
5Y
1D
Harrow Health Stockholders Approve Directors and Executive Pay
TipRanks · 4d ago
Harrow holds annual shareholder meeting, elects four directors
PUBT · 4d ago
Weekly Report: what happened at HROW last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at HROW last week (0608-0612)?
Weekly Report · 06/15 10:01
Harrow Adds Another Piece To Ophthalmology Strategy
Benzinga · 06/11 15:42
Harrow Shares Rise on Relaunch of Pediatric Eye Disease Treatment
Dow Jones · 06/10 15:08
Analyst Reiterates Buy on Harrow Health, Citing Verkazia Relaunch and Upcoming Iheezo Data as Key Growth Catalysts
TipRanks · 06/10 13:55
Analysts’ Top Healthcare Picks: Insmed (INSM), Harrow Health (HROW)
TipRanks · 06/10 13:20
More
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

Webull offers Harrow Inc stock information, including NASDAQ: HROW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HROW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HROW stock methods without spending real money on the virtual paper trading platform.